Table 1.

Distribution of disease in patients with castrate-metastatic prostate cancer

CategoryOverallMemorial Sloan-Kettering Cancer Center
Total no. of patients reviewed171116
TEC (1997-1999)4940
Hi-TEC (1999-2000)3024
Epothilone (2001-2003)9852
Median PSA at baseline (all studies)97.9 (range, 0.52-2,282.2)91.4 (range, 0.52-2,282.15)
Number of patients with
    bone only51 (29.8%)35 (30.2%)
    bone and soft tissue95 (55.6%)63 (54.3%)
    soft tissue only25 (14.6%)18 (15.5%)
  • *Thirty-nine percent to 40% had “measurable disease” (including visceral disease).